PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23545664-5	2013	The equality of variance of systolic (S)BP (i.e., the intragroup standard deviation of SBP) in the irbesartan group was significantly smaller than that observed in the olmesartan group at follow-up.	Irbesartan	99-109	selenium binding protein 1	Homo sapiens	87-90	
15897788-4	2005	SBP and DBP were reduced from 150 to 134 mm Hg and from 94 to 83 mm Hg, respectively, with irbesartan (P < 0.01).	Irbesartan	91-101	selenium binding protein 1	Homo sapiens	0-3	
12681201-7	2003	Irbesartan therapy led to a significant (p = 0.0001) decrease in SBP (from 170.9 18.4 to 138.5 16.5 mmHg) and DBP (from 96.6 11 to 82 9 mmHg).	Irbesartan	0-10	selenium binding protein 1	Homo sapiens	65-68	
12522893-6	2002	SBP was reduced in irbesartan group from 157.7 +/- 11.2 to 131.0 +/- 8.7 mmHg (12th week, p < 0.001).	Irbesartan	19-29	selenium binding protein 1	Homo sapiens	0-3	
8797143-8	1996	There was a dose-related decrease in supine and erect systolic and diastolic BP (SBP, DBP) with irbesartan from 10 mg and beyond, with no change in HR.	Irbesartan	96-106	selenium binding protein 1	Homo sapiens	81-84	
17315536-10	2006	The Emax values for the inhibitory effects on SBP and DBP of irbesartan were 14.8 +/- 1.5 and 9.8 +/- 2.1 mmHg respectively, the EC50 values were 0.29 +/- 0.11 and 0.18 +/- 0.07 microg x ml(-1), while the K(eo) values were 0.62 +/- 0.09 and 0.68 +/- 0.07 h(-1), respectively.	Irbesartan	61-71	selenium binding protein 1	Homo sapiens	46-49	
15071488-5	2004	Both combination treatments, delapril-manidipine and irbesartan-hydrochlorothiazide, produced a greater reduction in systolic BP/diastolic BP (SBP/DBP) values (-27.6/21.8 mmHg and -26.4/20.2 mmHg, respectively) than the respective monotherapies (-15.2/11.7 mmHg with delapril and -16.3/11.3 mmHg with irbesartan).	Irbesartan	53-63	selenium binding protein 1	Homo sapiens	143-146	
21346624-6	2011	RESULTS: When stratified by genotypes, patients carrying allele C of single-neucleotide polymorphism (SNP) rs5186 showed positive association between irbesartan concentration and BP response [SBP: beta +- SE=6.1 +- 2.3 with false discovery rate (FDR) P=0.029; DBP: beta +- SE=2.7 +- 1.0 with FDR P=0.029], but this was not seen in patients with AA genotype.	Irbesartan	150-160	selenium binding protein 1	Homo sapiens	192-195	
21346624-7	2011	There was a significant interaction between plasma irbesartan concentration and SNP rs5186 on SBP response (interaction P=0.0335) and DBP response (interaction P=0.0190).	Irbesartan	51-61	selenium binding protein 1	Homo sapiens	94-97	
21346624-8	2011	There also were significant interactions between plasma irbesartan concentration and hap3, hap5 and hap6 (constructed by four genotyped SNPs) on SBP response (FDR P<0.001), but not on DBP response.	Irbesartan	56-66	selenium binding protein 1	Homo sapiens	145-148	
18681815-6	2008	RESULTS: Treatment with irbesartan/HCTZ was associated with significant mean reductions in BP (intent-to-treat population, n = 370; SBP/DBP: -22.9/-10.3 +/- 14.7/8.8 mm Hg).	Irbesartan	24-34	selenium binding protein 1	Homo sapiens	132-135	
17407587-11	2007	RESULTS: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome.	Irbesartan	34-44	selenium binding protein 1	Homo sapiens	115-118	
17407587-13	2007	Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure reduction (SBP: -27.5 +/- 10.1 mmHg/DBP: -14.1 +/- 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0 +/- 6.8 mg/dl in men, +3.4 +/- 6.8 in women, both p < 0.0001), triglycerides (-34.1 +/- 52.6 mg/dl, p < 0.0001), fasting blood glucose (-10.0 +/- 24.7, p < 0.0001) and waist circumference (-3.2 +/- 12.7 cm in men, -1.7 +/- 14.4 in women, both p < 0.0001).	Irbesartan	0-10	selenium binding protein 1	Homo sapiens	113-116